Document
IPR2023-00724, No. 2652 Exhibit - EX2652 Excerpt of Reply Expert Report of William J Jusko, PhD Re garding Invalidity of US Patent No 10,335,462, In re Ozempic Semaglutide Patent Litigation, No 122
Cite Document
IPR2023-00724, No. 2652 Exhibit - EX2652 Excerpt of Reply Expert Report of William J Jusko, PhD Re garding Invalidity of US Patent No 10,335,462, In re Ozempic Semaglutide Patent Litigation, No 122
+ More Snippets
Document
IPR2023-00724, No. 1134 Exhibit - Exhibit 1134 39th Orange Book (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1134 Exhibit - Exhibit 1134 39th Orange Book (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1306 Exhibit - Exhibit 1306 Coca Decl (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1306 Exhibit - Exhibit 1306 Coca Decl (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2376 Exhibit - EX2376 Kalra, S, Sodium Glucose Co Transporter 2 SGLT2 Inhibitors A Review of Their Basic and Clinical Pharmacology, Diabetes Ther, 2014 Dec 52355 36...
Cite Document
IPR2023-00724, No. 2376 Exhibit - EX2376 Kalra, S, Sodium Glucose Co Transporter 2 SGLT2 Inhibitors A Review of Their Basic and Clinical Pharmacology, Diabetes Ther, 2014 Dec 52355 366 (P.T.A.B. Jan
+ More Snippets
Document
IPR2023-00724, No. 2499 Exhibit - EX2499 Novo Nordisk, Financial report for the period 1 January 2019 to 30 June 2019 Aug 9, 2019 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2499 Exhibit - EX2499 Novo Nordisk, Financial report for the period 1 January 2019 to 30 June 2019 Aug 9, 2019 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2107 Exhibit - EX2107 Ozempic FDA Approval Letter for sNDA March 28, 2022 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2107 Exhibit - EX2107 Ozempic FDA Approval Letter for sNDA March 28, 2022 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2502 Exhibit - EX2502 Novo Nordisk, Financial report for the period 1 January 2020 to 31 March 2020 May 6, 2020 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2502 Exhibit - EX2502 Novo Nordisk, Financial report for the period 1 January 2020 to 31 March 2020 May 6, 2020 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2523 Exhibit - EX2523 Eli Lilly Co, SEC Form 10 K for the Year Ended December 31, 2022 Feb 22, 2023 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2523 Exhibit - EX2523 Eli Lilly Co, SEC Form 10 K for the Year Ended December 31, 2022 Feb 22, 2023 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2384 Exhibit - EX2384 Clamp, LD, et al, Enhanced insulin sensitivity in successful, long term weight loss maintainers compared with matched controls with no weight loss his...
Cite Document
IPR2023-00724, No. 2384 Exhibit - EX2384 Clamp, LD, et al, Enhanced insulin sensitivity in successful, long term weight loss maintainers compared with matched controls with no weight loss history, N
+ More Snippets
Document
IPR2023-00724, No. 2432 Exhibit - EX2432 Invokana® Prescribing Information rev July 2017 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2432 Exhibit - EX2432 Invokana® Prescribing Information rev July 2017 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2417 Exhibit - EX2417 AstraZeneca, “AstraZeneca and Bristol Myers Squibb complete expansion of diabetes alliance through Bristol Myers Squibb’s acquisition of Amylin P...
Cite Document
IPR2023-00724, No. 2417 Exhibit - EX2417 AstraZeneca, “AstraZeneca and Bristol Myers Squibb complete expansion of diabetes alliance through Bristol Myers Squibb’s acquisition of Amylin Pharmaceutica
+ More Snippets
Document
IPR2023-00724, No. 2504 Exhibit - EX2504 Novo Nordisk, Financial report for the period 1 January 2020 to 30 September 2020 Oct 30, 2020 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2504 Exhibit - EX2504 Novo Nordisk, Financial report for the period 1 January 2020 to 30 September 2020 Oct 30, 2020 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2501 Exhibit - EX2501 Novo Nordisk, Financial report for the period 1 January 2019 to 31 December 2019 Feb 5, 2020 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2501 Exhibit - EX2501 Novo Nordisk, Financial report for the period 1 January 2019 to 31 December 2019 Feb 5, 2020 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2064 Exhibit - EX2064 Synapse, “Pegylated GLP 1 analogue LY2428757 – Eli Lilly Co,” available at httpssynapsepatsnapcomdrug482a547adeba4170ab23efa225fb966d l...
Cite Document
IPR2023-00724, No. 2064 Exhibit - EX2064 Synapse, “Pegylated GLP 1 analogue LY2428757 – Eli Lilly Co,” available at httpssynapsepatsnapcomdrug482a547adeba4170ab23efa225fb966d last updated December
+ More Snippets
Document
IPR2023-00724, No. 1102 Exhibit - Exhibit 1102 Rubio Herrera (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1102 Exhibit - Exhibit 1102 Rubio Herrera (P.T.A.B. May. 22, 2024)
+ More Snippets